Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.
Atomo Diagnostics's Sloan Ratio for the quarter that ended in Dec. 2025 was -18.39%.
Warning Sign:
When sloan ratio (-32.1)% higher than 25% or lower than -25%, earnings are more likely to be made up of accruals.
As of Dec. 2025, Atomo Diagnostics has a Sloan Ratio of -18.39%, indicating earnings are more likely to be made up of accruals.
Atomo Diagnostics (ASX:AT1) Sloan Ratio % Explanation
A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.
If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.
If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.
If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.
As of Dec. 2025, Atomo Diagnostics has a Sloan Ratio of -18.39%, indicating earnings are more likely to be made up of accruals.
Atomo Diagnostics Sloan Ratio % Related Terms
Atomo Diagnostics Sloan Ratio % Historical Data
* Premium members only.
The historical data trend for Atomo Diagnostics's Sloan Ratio % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:AT1 vs ABT, SYK, MDT: Sloan Ratio % Comparison
For the Medical Devices subindustry, Atomo Diagnostics's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Atomo Diagnostics Sloan Ratio % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Atomo Diagnostics's Sloan Ratio % distribution charts can be found below:
* The bar in red indicates where Atomo Diagnostics's Sloan Ratio % falls into.
Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.
Atomo Diagnostics's Sloan Ratio for the fiscal year that ended in Jun. 2025 is calculated as
For company reported semi-annually, GuruFocus uses latest two semi-annual data as the TTM data.
Atomo Diagnostics's Net Income for the trailing twelve months (TTM) ended in Dec. 2025 was -2.212 (Jun. 2025 ) + -1.765 (Dec. 2025 ) = A$-3.98 Mil.
Atomo Diagnostics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was -1.232 (Jun. 2025 ) + -0.963 (Dec. 2025 ) = A$-2.20 Mil.
Atomo Diagnostics's Cash Flow from Investing for the trailing twelve months (TTM) ended in Dec. 2025 was 0.007 (Jun. 2025 ) + -0.046 (Dec. 2025 ) = A$-0.04 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Atomo Diagnostics (ASX:AT1) has a Sloan Ratio % of -18.39% as of Dec. 2025. Sloan ratio measures earnings quality based on the amount of accruals. View historical data on Atomo Diagnostics and its competitors.
Is Atomo Diagnostics' Sloan Ratio % too high?
Atomo Diagnostics' current Sloan Ratio % is -18.39%.
How does Atomo Diagnostics' Sloan Ratio % compare to ABT and SYK?
Atomo Diagnostics' Sloan Ratio % of -18.39% can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Sloan Ratio % for a Medical Devices & Instruments company?
A good Sloan Ratio % depends on the Medical Devices & Instruments industry context. However, Sloan Ratio % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Sloan Ratio % mean?
A high Sloan Ratio % can signal that a stock is expensive relative to its fundamentals. Sloan ratio measures earnings quality based on the amount of accruals. View historical data on Atomo Diagnostics and its competitors. Atomo Diagnostics's current Sloan Ratio % is -18.39%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Atomo Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, Atomo Diagnostics (ASX:AT1) is currently considered Modestly Undervalued. The stock's GF Value™ is A$0.02, compared to a current price of A$0.02 — trading 15% below its estimated fair value. The current Sloan Ratio % is -18.39%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Sloan Ratio % calculated?
Sloan Ratio % is calculated from a company's financial statements. For Atomo Diagnostics (ASX:AT1), the current Sloan Ratio % is -18.39% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Atomo Diagnostics Ltd is an Australian medical device design innovator and original equipment manufacturing company. The company is engaged in the development and sale of medical devices. The company develops point-of-care devices for rapid diagnostic testing. The company offers AtomoRapid RDT Platform with devices including Galileo, Pascal, Curie, and Elion. The firm operates in a single segment, medical device research and development.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:AT1 has been successfully added to your 
